CHATTEM, INC D/B/A OPELLA

Lobbying for CHATTEM, INC D/B/A OPELLA · Healthcare related to nonprescription drugs and dietary supplements.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $150,000.00 expenses · posted Apr 20, 2026

Lobbying activity 3

Health Issues

OTC regulatory pathways - OMUFA and Rx to OTC Switch, Dietary Supplement regulation

Trade (domestic/foreign)

Tariffs

Budget/Appropriations

Rx to OTC Switch (FDA) and chain of custody

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.